Geneos Wealth Management Inc. Ionis Pharmaceuticals Inc Transaction History

Geneos Wealth Management Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$36.54 - $48.66 $110,898 - $147,683	-3,035 Reduced 88.36%	400 $17,000
Q2 2022 Jul 22, 2022	SELL	$31.71 - $43.0 $51,623 - $70,004	-1,628 Reduced 32.15%	3,435 $127,000
Q1 2022 May 16, 2022	SELL	$29.88 - $37.04 $89 - $111	-3 Reduced 0.06%	5,063 $187,000
Q4 2021 Feb 09, 2022	BUY	$25.61 - $35.1 $5,839 - $8,002	228 Added 4.71%	5,066 $154,000
Q3 2021 Nov 09, 2021	BUY	$33.54 - $40.55 $4,494 - $5,433	134 Added 2.85%	4,838 $162,000
Q2 2021 Jul 08, 2021	SELL	$34.54 - $47.25 $14,610 - $19,986	-423 Reduced 8.25%	4,704 $187,000
Q1 2021 Jun 17, 2021	SELL	$42.51 - $63.78 $26,016 - $39,033	-612 Reduced 10.66%	5,127 $219,000
Q4 2020 May 19, 2021	BUY	$45.3 - $60.27 $259,976 - $345,889	5,739 New	5,739 $242,000
Q1 2018 Sep 07, 2021	SELL	$44.08 - $55.05 $4,408 - $5,505	-100 Closed	0 $0
Q4 2017 Sep 07, 2021	BUY	$50.3 - $64.39 $5,030 - $6,439	100 New	100 $5,000
Q1 2017 Sep 07, 2021	SELL	N/A	-480 Closed	0 $0
Q2 2016 Sep 07, 2021	SELL	N/A	-84 Reduced 14.89%	480 $11,000
Q1 2016 Sep 07, 2021	BUY	N/A	564	564 $23,000

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

Stay updated on Geneos Wealth Management Inc. with notifications on news.